Adherex Technologies (FENC) Competitors $8.16 -0.16 (-1.86%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FENC vs. IMNM, ZYME, AKBA, MLYS, TRVI, LENZ, NRIX, URGN, NUVB, and SIONShould you be buying Adherex Technologies stock or one of its competitors? The main competitors of Adherex Technologies include Immunome (IMNM), Zymeworks (ZYME), Akebia Therapeutics (AKBA), Mineralys Therapeutics (MLYS), Trevi Therapeutics (TRVI), LENZ Therapeutics (LENZ), Nurix Therapeutics (NRIX), Urogen Pharma (URGN), Nuvation Bio (NUVB), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. Adherex Technologies vs. Its Competitors Immunome Zymeworks Akebia Therapeutics Mineralys Therapeutics Trevi Therapeutics LENZ Therapeutics Nurix Therapeutics Urogen Pharma Nuvation Bio Sionna Therapeutics Adherex Technologies (NASDAQ:FENC) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Which has stronger valuation & earnings, FENC or IMNM? Adherex Technologies has higher revenue and earnings than Immunome. Adherex Technologies is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdherex Technologies$47.54M4.76-$440K-$0.51-16.01Immunome$9.04M105.93-$292.96M-$3.18-3.46 Which has more risk and volatility, FENC or IMNM? Adherex Technologies has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Do insiders & institutionals hold more shares of FENC or IMNM? 55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 11.0% of Adherex Technologies shares are owned by insiders. Comparatively, 8.6% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer FENC or IMNM? In the previous week, Immunome had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 4 mentions for Immunome and 2 mentions for Adherex Technologies. Immunome's average media sentiment score of 0.89 beat Adherex Technologies' score of 0.34 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is FENC or IMNM more profitable? Adherex Technologies has a net margin of -45.52% compared to Immunome's net margin of -1,875.21%. Adherex Technologies' return on equity of 0.00% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Adherex Technologies-45.52% N/A -26.37% Immunome -1,875.21%-71.65%-60.36% Do analysts prefer FENC or IMNM? Adherex Technologies presently has a consensus target price of $13.00, suggesting a potential upside of 59.22%. Immunome has a consensus target price of $23.33, suggesting a potential upside of 112.01%. Given Immunome's higher possible upside, analysts plainly believe Immunome is more favorable than Adherex Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adherex Technologies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAdherex Technologies beats Immunome on 10 of the 17 factors compared between the two stocks. Get Adherex Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FENC vs. The Competition Export to ExcelMetricAdherex TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$224.14M$3.03B$5.55B$9.44BDividend YieldN/A2.46%4.73%4.14%P/E Ratio-15.8517.8029.0024.17Price / Sales4.76182.27371.7778.54Price / Cash242.7640.5624.4827.20Price / Book-38.888.898.635.79Net Income-$440K-$54.98M$3.24B$264.91M7 Day Performance-4.39%1.88%0.05%-1.27%1 Month Performance-5.99%16.75%7.65%5.47%1 Year Performance42.50%14.34%29.63%23.03% Adherex Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FENCAdherex Technologies1.8281 of 5 stars$8.17-1.9%$13.00+59.2%+44.4%$224.14M$47.54M-15.8510News CoverageUpcoming EarningsIMNMImmunome2.016 of 5 stars$10.84-0.3%$23.33+115.3%-20.6%$945.82M$9.04M-3.4140Upcoming EarningsZYMEZymeworks3.0592 of 5 stars$13.46+1.0%$21.00+56.0%+23.5%$937.93M$93.38M-8.97460Upcoming EarningsAKBAAkebia Therapeutics3.8167 of 5 stars$3.59+0.8%$6.75+88.0%+200.8%$934.98M$160.18M-17.09430Upcoming EarningsMLYSMineralys Therapeutics2.5729 of 5 stars$13.60-5.0%$32.25+137.1%+10.1%$933.31MN/A-3.6528Upcoming EarningsTRVITrevi Therapeutics2.991 of 5 stars$7.64-2.9%$20.88+173.2%+160.5%$923.09MN/A-16.9820Upcoming EarningsLENZLENZ Therapeutics1.694 of 5 stars$31.51-0.3%$48.60+54.2%+22.1%$889.98MN/A-17.80110Earnings ReportAnalyst RevisionNRIXNurix Therapeutics2.5096 of 5 stars$11.93+3.6%$29.31+145.7%-45.7%$880.69M$88.38M-4.57300Positive NewsURGNUrogen Pharma4.6197 of 5 stars$18.90-0.3%$32.86+73.8%+26.8%$875.52M$90.40M-5.94200Upcoming EarningsAnalyst ForecastNUVBNuvation Bio2.0269 of 5 stars$2.55+2.0%$7.17+181.0%-31.3%$850.66M$7.87M-1.0960Upcoming EarningsSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Positive NewsLockup Expiration Related Companies and Tools Related Companies Immunome Alternatives Zymeworks Alternatives Akebia Therapeutics Alternatives Mineralys Therapeutics Alternatives Trevi Therapeutics Alternatives LENZ Therapeutics Alternatives Nurix Therapeutics Alternatives Urogen Pharma Alternatives Nuvation Bio Alternatives Sionna Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FENC) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adherex Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adherex Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FENC Stock Alerts